In a patient taking trazodone who is experiencing sundowning and wandering with melatonin ineffective, how should the management be adjusted?

Discontinue Trazodone and Consider Low-Dose Atypical Antipsychotics or Environmental Interventions

You should discontinue trazodone, as guidelines explicitly recommend against its use for sleep disturbances, and consider alternative pharmacologic agents such as low-dose quetiapine (2.5-5 mg) or focus on non-pharmacologic interventions for sundowning and wandering. 1, 2, 3

Why Trazodone Should Be Stopped

The 2017 American Academy of Sleep Medicine guidelines explicitly state that clinicians should NOT use trazodone for treatment of sleep onset or sleep maintenance insomnia based on low-quality evidence showing minimal benefit 1. The 2020 VA/DoD guidelines reinforce this, noting that trazodone's adverse effect profile outweighs its limited efficacy 2.

Critical safety concerns with trazodone include:

• Cardiac arrhythmias and QT prolongation (even at doses ≤100 mg) 3
• Orthostatic hypotension and falls risk—particularly dangerous in elderly patients with wandering behaviors 3
• Serotonin syndrome risk, especially if combined with other serotonergic agents 3
• Priapism (in males) 3

The FDA label explicitly warns about these risks, making trazodone particularly problematic in elderly patients with dementia who are already at high fall risk 3.

Addressing Sundowning and Wandering

Sundowning and wandering are behavioral and psychological symptoms of dementia (BPSD), not simply insomnia. This distinction is crucial because the treatment approach differs fundamentally.

First-Line: Non-Pharmacologic Interventions

Before adding medications, implement these evidence-based strategies 4:

• Environmental modifications: Ensure adequate lighting in evening hours, remove hazards, install grab bars, use labels and task lighting
• Structured routines: Establish consistent daily schedules with meaningful activities during the day
• Pain management: Assess and treat underlying pain (arthritis, other sources) that may trigger agitation
• Caregiver education: Train caregivers on communication techniques (calm tone, simple single-step commands, avoid confrontation)
• Safety measures: Secure dangerous objects, ensure safe navigation between rooms

Pharmacologic Options When Non-Pharmacologic Measures Fail

For persistent sundowning with agitation/wandering after environmental interventions:

1. Low-dose atypical antipsychotics (use cautiously, shortest duration possible):

   • Quetiapine 2.5-5 mg at bedtime 5
   • Monitor for metabolic effects, sedation, and increased mortality risk (FDA black box warning in elderly with dementia)

2. Consider doxepin 3-6 mg if sleep maintenance is the primary issue without significant behavioral disturbance 1

   • This is the only antidepressant with positive guideline recommendation for sleep maintenance insomnia
   • Lower anticholinergic burden at these low doses compared to higher doses

What About Melatonin?

You mentioned melatonin was ineffective. The evidence supports this finding—melatonin (up to 10 mg) shows no significant benefit for sleep outcomes in moderate-to-severe Alzheimer's disease 6, 7. The 2017 AASM guidelines recommend against melatonin for chronic insomnia 1.

However, some older observational studies suggest melatonin (6-9 mg) may reduce sundowning specifically 8, though this wasn't confirmed in higher-quality RCTs 6, 7. Given it failed in your patient, don't continue it.

Alternative Sleep Medications (If Needed)

If a hypnotic is absolutely necessary for severe insomnia component:

• Avoid benzodiazepines entirely—high fall risk, cognitive impairment, and guidelines recommend against use in elderly 1, 2
• Avoid Z-drugs (zolpidem, eszopiclone)—similar concerns in elderly with dementia, risk of complex sleep behaviors 1
• Ramelteon 8 mg showed no benefit in mild-to-moderate AD 6, 7

Clinical Algorithm

1. Immediately discontinue trazodone due to safety concerns and lack of efficacy
2. Assess and treat pain (if present, this alone may reduce agitation)
3. Implement environmental modifications and caregiver training (highest priority)
4. If behavioral symptoms persist after 2-4 weeks:
   • Consider low-dose quetiapine 2.5-5 mg at bedtime for sundowning/agitation
   • OR doxepin 3-6 mg if pure sleep maintenance issue without agitation
5. Monitor closely for adverse effects (falls, sedation, metabolic changes)
6. Reassess regularly and attempt to taper/discontinue pharmacologic agents once behaviors stabilize

Critical Pitfalls to Avoid

• Don't treat sundowning as simple insomnia—it requires behavioral interventions, not just sleep medications
• Don't continue ineffective medications (melatonin in this case)
• Don't use antihistamines (diphenhydramine)—strong anticholinergic effects, worsens cognition 1, 2
• Don't use benzodiazepines—falls, confusion, paradoxical agitation in elderly 1, 9, 2
• Don't ignore underlying causes—pain, constipation, urinary retention, infections can all trigger behavioral symptoms 4

The evidence strongly supports stopping trazodone and prioritizing non-pharmacologic interventions, with cautious use of low-dose atypical antipsychotics only if behavioral strategies fail and symptoms significantly impair quality of life or safety.